Using pain quality assessment measures for selecting analgesic agents

Clinical Journal of Pain

Volumn 22, Issue SUPPL. 1, 2006, Pages

  Jensen, Mark P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Measures; Pain assessment; Pain quality

Indexed keywords

ANALGESIC AGENT; CAPSAICIN; LIDOCAINE; OXYCODONE; PHENTOLAMINE;

HUMAN; INJECTION SITE PAIN; NEUROPATHIC PAIN; NOCICEPTION; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; TREATMENT OUTCOME; EVALUATION;

ANALGESICS; EVALUATION STUDIES; HUMANS; PAIN; PAIN MEASUREMENT;

EID: 33644876484     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ajp.0000193829.45571.4f     Document Type: Review

References (19)

1. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277-299.
2. Melzack R. The Short-Form McGill Pain Questionnaire. Pain. 1987;30:191-197.
3. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332-338.
4. Yang JC, Clark WC, Tsui SL, et al. Preoperative multidimensional affect and pain survey (MAPS) scores predict postcolectomy analgesia requirement. Clin J Pain. 2000;16:314-320.
5. Bennett M. The LANSS Pain Scale: the Leeds Assessment of Neuropathic Symptoms and Signs. Pain. 2001;92:147-157.
6. Krause SJ, Backonja M-M. Development of a Neuropathic Pain Questionnaire. Clin J Pain. 2003;19:306-314.
7. Backonja M-M, Krause SJ. Neuropathic Pain Questionnaire-Short Form. Clin J Pain. 2003;19:315-316.
8. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248-257.
9. Jensen MP. Pain assessment in clinical trials. In: Carr D, Wittink H, eds. Evidence, Outcomes, and Quality of Life in Pain Treatment. Amsterdam: Elsevier; In press.
10. Bennett MI, Smith BH, Torrance N, et al. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149-158.
11. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29-36.
12. Turk DC, Rudy TE, Salovey P. The McGill Pain Questionnaire reconsidered: confirming the factor structure and examining appropriate uses. Pain. 1985;21:385-397.
13. Melzack R, Katz J. The McGill Pain Questionnaire: appraisal and current status. In: Turk DC, Melzack R, eds. Handbook of Pain Assessment, 2nd ed. New York: Guilford Press, 2001:35-52.
14. Chang PF, Arendt-Nielsen L, Graven-Nielsen T, et al. Comparative EEG activation to skin pain and muscle pain induced by capsaicin injection. Int J Psychophysiol. 2004;51:117-126.
15. Jensen MP, Dworkin RH, Gammaitoni AR, et al. Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain. 2005;6:98-106.
16. Levendoglu F, Ogun CO, Ozerbil O, et al. Gabapentin is a first-line drug for the treatment of neuropathic pain in spinal cord injury. Spine. 2004;28:743-751.
17. Semenchuk MR, Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. J Pain. 2000;1:285-292.
18. Potter J, Higginson IJ, Scadding JW, et al. Identifying neuropathic pain in patients with head and neck cancer: use of the Leeds Assessment of Neuropathic Symptoms and Signs Scale. J R Soc Med. 2003;96:379-383.
19. Yucel A, Senocak M, Kocasoy Orhan E, et al. Results of the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale in Turkey: a validation study. J Pain. 2004;5:427-432.